Trilaciclib + Pembrolizumab + Gemcitabine + Carboplatin
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Triple-Negative Breast Cancer
Conditions
Metastatic Triple-Negative Breast Cancer
Trial Timeline
Jan 10, 2024 → Mar 1, 2027
NCT ID
NCT06027268About Trilaciclib + Pembrolizumab + Gemcitabine + Carboplatin
Trilaciclib + Pembrolizumab + Gemcitabine + Carboplatin is a phase 2 stage product being developed by Merck for Metastatic Triple-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06027268. Target conditions include Metastatic Triple-Negative Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Triple-Negative Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06027268 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic Triple-Negative Breast Cancer